다우존스 지수

실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Chemomab Therapeutics Ltd (CMMB)
Chemomab Therapeutics Ltd (CMMB) 뉴스

CMMB

Chemomab Therapeutics (CMMB)

Chemomab Therapeutics Ltd

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:CMMB

1 2 3 4 5 6 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/02	20:00	GlobeNewswire Inc.	Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/04/24	20:00	GlobeNewswire Inc.	Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/04/18	20:00	GlobeNewswire Inc.	Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/04/02	20:00	GlobeNewswire Inc.	Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/03/25	20:06	GlobeNewswire Inc.	Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/03/07	21:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/03/07	21:00	PR Newswire (US)	Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/03/05	21:00	PR Newswire (US)	Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/02/20	23:20	AllPennyStocks.com	Biotech Shares Massively Bid Up Before Opening Bell	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/02/20	21:00	PR Newswire (US)	Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/02/14	21:00	PR Newswire (US)	Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/02/05	21:00	PR Newswire (US)	Chemomab Therapeutics to Participate in Upcoming Investor Conferences	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/01/30	21:00	PR Newswire (US)	Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/01/03	21:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2024/01/03	21:00	PR Newswire (US)	Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/11/16	21:00	PR Newswire (US)	Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/11/16	06:35	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/11/15	21:00	PR Newswire (US)	Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/11/13	22:00	PR Newswire (US)	Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/11/09	22:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/11/09	22:00	PR Newswire (US)	Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/11/07	06:15	PR Newswire (US)	Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/11/06	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/10/30	21:33	Edgar (US Regulatory)	Form F-3/A - Registration statement by foreign private issuers: [Amend]	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/10/30	20:00	PR Newswire (US)	Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/10/26	20:00	PR Newswire (US)	Chemomab Therapeutics to Present at Upcoming Scientific Conferences	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/10/17	05:25	Edgar (US Regulatory)	Form F-3 - Registration statement by foreign private issuers	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/09/28	20:00	PR Newswire (US)	Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/08/29	20:00	PR Newswire (US)	Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:CMMB	Chemomab Therapeutics Ltd
2023/08/14	21:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMMB	Chemomab Therapeutics Ltd

검색 관련기사 보기:NASDAQ:CMMB

1 2 3 4 5 6 다음 >>

Gold vs US Dollar

Invesco QQQ Trust Series 1

US Dollar vs Euro

American Express

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관